S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
DIS   130.26 (-0.48%)
Log in

Quest Diagnostics Stock Price, News & Analysis (NYSE:DGX)

$102.17
-0.49 (-0.48 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$102.01
Now: $102.17
$103.00
50-Day Range
$101.68
MA: $104.56
$107.42
52-Week Range
$78.95
Now: $102.17
$107.97
Volume79,893 shs
Average Volume806,962 shs
Market Capitalization$13.76 billion
P/E Ratio16.19
Dividend Yield2.02%
Beta0.87
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP74834L10
Phone973-520-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.53 billion
Cash Flow$7.94 per share
Book Value$38.71 per share

Profitability

Net Income$736 million

Miscellaneous

Employees46,000
Market Cap$13.76 billion
Next Earnings Date10/22/2019 (Confirmed)
OptionableOptionable

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.


Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics announced a quarterly dividend on Thursday, August 15th. Shareholders of record on Friday, October 4th will be paid a dividend of $0.53 per share on Monday, October 21st. This represents a $2.12 dividend on an annualized basis and a yield of 2.07%. The ex-dividend date is Thursday, October 3rd. View Quest Diagnostics' Dividend History.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) posted its quarterly earnings data on Tuesday, July, 23rd. The medical research company reported $1.73 earnings per share for the quarter, beating analysts' consensus estimates of $1.69 by $0.04. The medical research company had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.94 billion. Quest Diagnostics had a net margin of 9.64% and a return on equity of 15.05%. The company's quarterly revenue was up 1.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.75 EPS. View Quest Diagnostics' Earnings History.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for Quest Diagnostics.

How can I listen to Quest Diagnostics' earnings call?

Quest Diagnostics will be holding an earnings conference call on Tuesday, October 22nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY19 earnings guidance on Tuesday, July, 23rd. The company provided earnings per share guidance of >$6.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.46. The company issued revenue guidance of $7.6-7.75 billion, compared to the consensus revenue estimate of $7.69 billion.

What price target have analysts set for DGX?

18 equities research analysts have issued 1 year price targets for Quest Diagnostics' stock. Their predictions range from $85.00 to $121.00. On average, they expect Quest Diagnostics' share price to reach $104.87 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price. View Analyst Price Targets for Quest Diagnostics.

What is the consensus analysts' recommendation for Quest Diagnostics?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 3 sell ratings, 7 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Quest Diagnostics.

What are Wall Street analysts saying about Quest Diagnostics stock?

Here are some recent quotes from research analysts about Quest Diagnostics stock:
  • 1. According to Zacks Investment Research, "In recent times, Quest Diagnostics has been refocusing on its diagnostic information services wing and disciplined capital deployment. Its acquisitions and collaborations with hospitals continue to act as key drivers. We are upbeat about Quest Diagnostics’ Preferred Network partnership with UnitedHealthcare. In the past three months, the company has outperformed its industry. The company exited second-quarter 2019 with better-than-expected earnings as well as revenues On the flip side, the company is currently facing several reimbursement issues. Also, a rise in patient concession along with certain reserve adjustments caused a decline in revenue per requisition. Also, adjusted earnings declined on a year-over-year basis. This apart, escalating costs and a tough competitive landscape are concerns." (9/30/2019)
  • 2. Evercore ISI analysts commented, "We spent time on the west coast last week (LA + SF weather right now >>> Diagnostics (CFO and IR). Post solid 1H results after a reset in sentiment, numbers, and multiples last year, it is safe to say investor perception has recovered somewhat and the focus has shifted back towards the longer term path with the possibility of regulatory easing (particularly as organic volumes surprised last Q)." (8/8/2019)
  • 3. Canaccord Genuity analysts commented, "We have written before that large labs (LH, DGX) and most of the rest of the non- specialized lab industry will face major challenges in 2019 and beyond. That said, we believe Quest is better positioned than LabCorp as Quest is a share gainer related to the UNH contract. DGX indicated that its UNH volumes build each week, and we expect DGX will drive 2-3 points of to offset the ~260bps headwind related to reimbursement. We think the 2019 bar is set appropriately and DGX likely can recover more in 2H/19. DGX is paying a 2.4% dividend yield. We maintain our BUY, trim our estimates and our PT to $97, which uses a 14.4x multiple on our ’20 Adj. EPS of $6.75. Q4/18 results. Adj. EPS of $1.36 (-3% Y/Y%) matched our/Street’s ~$1.36, while revs of $1,839M (-1.4% Y/Y) missed our/Street’s ~$1,878M (+0.7%). Rev./req." (2/18/2019)
  • 4. Barclays PLC analysts commented, "We were surprised there was another leg down in the quarter, though one silver lining is that volume growth of 3.4% appears improved – and the company noted that 2019 is off to a good start. $1.36 was modestly better than our forecast of $1.35. Additionally, Quest had an active 4Q18 of capital deployment, repurchasing $175mm of stock, $200mm towards acquisitions, and $68mm toward dividends. Ultimately, shares now trade at 13x our new 2019 EPS forecast of $6.40, and we believe sentiment is near a trough despite the potential for leverageable share gains in 2019. In our view, structural trends should be at the back of the national labs to consolidate testing share – and this is Quest’s time to shine." (2/15/2019)

Has Quest Diagnostics been receiving favorable news coverage?

Media coverage about DGX stock has been trending somewhat positive recently, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Quest Diagnostics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Quest Diagnostics.

Are investors shorting Quest Diagnostics?

Quest Diagnostics saw a increase in short interest in September. As of September 30th, there was short interest totalling 3,940,000 shares, an increase of 9.1% from the August 30th total of 3,610,000 shares. Based on an average daily trading volume, of 941,600 shares, the days-to-cover ratio is currently 4.2 days. Approximately 2.9% of the company's stock are short sold. View Quest Diagnostics' Current Options Chain.

Who are some of Quest Diagnostics' key competitors?

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Honeywell International (HON), Micron Technology (MU), United Rentals (URI), Accenture (ACN) and AutoZone (AZO).

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the folowing people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 62)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 57)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 56)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 56)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 44)

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.15%), Sabal Trust CO (0.15%), Robeco Institutional Asset Management B.V. (0.13%), Crossmark Global Holdings Inc. (0.09%), DNB Asset Management AS (0.08%) and Gateway Investment Advisers LLC (0.07%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Everett Cunningham, Gail R Wilensky, J E Davis, Jeffrey M Leiden, Jon R Cohen, Mark Guinan, Michael E Prevoznik, Michael J Deppe, Robert A Klug and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics.

Which institutional investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including Brinker Capital Inc., Gateway Investment Advisers LLC, DNB Asset Management AS, Sage Capital Advisors llc, Crossmark Global Holdings Inc., First Hawaiian Bank, CenturyLink Investment Management Co and Wedbush Securities Inc.. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Everett Cunningham, Gail R Wilensky, J E Davis, Mark Guinan, Michael E Prevoznik, Michael J Deppe and Stephen H Rusckowski. View Insider Buying and Selling for Quest Diagnostics.

Which institutional investors are buying Quest Diagnostics stock?

DGX stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Robeco Institutional Asset Management B.V., Zurcher Kantonalbank Zurich Cantonalbank , Nisa Investment Advisors LLC, CX Institutional, State of Alaska Department of Revenue, Denali Advisors LLC and Calamos Advisors LLC. View Insider Buying and Selling for Quest Diagnostics.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $102.17.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $13.76 billion and generates $7.53 billion in revenue each year. The medical research company earns $736 million in net income (profit) each year or $6.31 on an earnings per share basis. Quest Diagnostics employs 46,000 workers across the globe.View Additional Information About Quest Diagnostics.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is http://www.questdiagnostics.com/.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]


MarketBeat Community Rating for Quest Diagnostics (NYSE DGX)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  420 (Vote Outperform)
Underperform Votes:  765 (Vote Underperform)
Total Votes:  1,185
MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Featured Article: What is the yield curve?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel